0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Cell-based Flu Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: December 2024
|
Report Code: QYRE-Auto-15P9763
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Cell based Flu Vaccine Market Research Report 2022
BUY CHAPTERS

Cell-based Flu Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-15P9763
Report
December 2024
Pages:124
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cell-based Flu Vaccine - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Cell-based Flu Vaccine - Market

Cell-based Flu Vaccine - Market

The global market for Cell-based Flu Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cell-based Flu Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cell-based Flu Vaccine by region & country, by Type, and by Application.
The Cell-based Flu Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell-based Flu Vaccine.
Market Segmentation

Scope of Cell-based Flu Vaccine - Market Report

Report Metric Details
Report Name Cell-based Flu Vaccine - Market
CAGR 5%
Segment by Type:
  • Trivalent Influenza Vaccine
  • Quadrivalent Influenza Vaccine
Segment by Application
  • Aldults
  • Children
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GlaxoSmithKline, Sanofi, Pfizer, MedImmune, LLC, Intravacc, CSL Limited, E. Merck KG, Novartis, Danaher Corporation, SINOVAC
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Cell-based Flu Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Cell-based Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Cell-based Flu Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Cell-based Flu Vaccine - Market report?

Ans: The main players in the Cell-based Flu Vaccine - Market are GlaxoSmithKline, Sanofi, Pfizer, MedImmune, LLC, Intravacc, CSL Limited, E. Merck KG, Novartis, Danaher Corporation, SINOVAC

What are the Application segmentation covered in the Cell-based Flu Vaccine - Market report?

Ans: The Applications covered in the Cell-based Flu Vaccine - Market report are Aldults, Children

What are the Type segmentation covered in the Cell-based Flu Vaccine - Market report?

Ans: The Types covered in the Cell-based Flu Vaccine - Market report are Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine

1 Market Overview
1.1 Cell-based Flu Vaccine Product Introduction
1.2 Global Cell-based Flu Vaccine Market Size Forecast
1.2.1 Global Cell-based Flu Vaccine Sales Value (2019-2030)
1.2.2 Global Cell-based Flu Vaccine Sales Volume (2019-2030)
1.2.3 Global Cell-based Flu Vaccine Sales Price (2019-2030)
1.3 Cell-based Flu Vaccine Market Trends & Drivers
1.3.1 Cell-based Flu Vaccine Industry Trends
1.3.2 Cell-based Flu Vaccine Market Drivers & Opportunity
1.3.3 Cell-based Flu Vaccine Market Challenges
1.3.4 Cell-based Flu Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cell-based Flu Vaccine Players Revenue Ranking (2023)
2.2 Global Cell-based Flu Vaccine Revenue by Company (2019-2024)
2.3 Global Cell-based Flu Vaccine Players Sales Volume Ranking (2023)
2.4 Global Cell-based Flu Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Cell-based Flu Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Cell-based Flu Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Cell-based Flu Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Cell-based Flu Vaccine
2.9 Cell-based Flu Vaccine Market Competitive Analysis
2.9.1 Cell-based Flu Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Cell-based Flu Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-based Flu Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Trivalent Influenza Vaccine
3.1.2 Quadrivalent Influenza Vaccine
3.2 Global Cell-based Flu Vaccine Sales Value by Type
3.2.1 Global Cell-based Flu Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cell-based Flu Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Cell-based Flu Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Cell-based Flu Vaccine Sales Volume by Type
3.3.1 Global Cell-based Flu Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Cell-based Flu Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Cell-based Flu Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Cell-based Flu Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Aldults
4.1.2 Children
4.2 Global Cell-based Flu Vaccine Sales Value by Application
4.2.1 Global Cell-based Flu Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cell-based Flu Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Cell-based Flu Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Cell-based Flu Vaccine Sales Volume by Application
4.3.1 Global Cell-based Flu Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Cell-based Flu Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Cell-based Flu Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Cell-based Flu Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Cell-based Flu Vaccine Sales Value by Region
5.1.1 Global Cell-based Flu Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cell-based Flu Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Cell-based Flu Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Cell-based Flu Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Cell-based Flu Vaccine Sales Volume by Region
5.2.1 Global Cell-based Flu Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Cell-based Flu Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Cell-based Flu Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Cell-based Flu Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Cell-based Flu Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Cell-based Flu Vaccine Sales Value, 2019-2030
5.4.2 North America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Cell-based Flu Vaccine Sales Value, 2019-2030
5.5.2 Europe Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Cell-based Flu Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Cell-based Flu Vaccine Sales Value, 2019-2030
5.7.2 South America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Cell-based Flu Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cell-based Flu Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cell-based Flu Vaccine Sales Value
6.2.1 Key Countries/Regions Cell-based Flu Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Cell-based Flu Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Cell-based Flu Vaccine Sales Value, 2019-2030
6.3.2 United States Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cell-based Flu Vaccine Sales Value, 2019-2030
6.4.2 Europe Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cell-based Flu Vaccine Sales Value, 2019-2030
6.5.2 China Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cell-based Flu Vaccine Sales Value, 2019-2030
6.6.2 Japan Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cell-based Flu Vaccine Sales Value, 2019-2030
6.7.2 South Korea Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cell-based Flu Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cell-based Flu Vaccine Sales Value, 2019-2030
6.9.2 India Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cell-based Flu Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Information
7.1.2 GlaxoSmithKline Introduction and Business Overview
7.1.3 GlaxoSmithKline Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 GlaxoSmithKline Cell-based Flu Vaccine Product Offerings
7.1.5 GlaxoSmithKline Recent Development
7.2 Sanofi
7.2.1 Sanofi Company Information
7.2.2 Sanofi Introduction and Business Overview
7.2.3 Sanofi Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sanofi Cell-based Flu Vaccine Product Offerings
7.2.5 Sanofi Recent Development
7.3 Pfizer
7.3.1 Pfizer Company Information
7.3.2 Pfizer Introduction and Business Overview
7.3.3 Pfizer Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Pfizer Cell-based Flu Vaccine Product Offerings
7.3.5 Pfizer Recent Development
7.4 MedImmune, LLC
7.4.1 MedImmune, LLC Company Information
7.4.2 MedImmune, LLC Introduction and Business Overview
7.4.3 MedImmune, LLC Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 MedImmune, LLC Cell-based Flu Vaccine Product Offerings
7.4.5 MedImmune, LLC Recent Development
7.5 Intravacc
7.5.1 Intravacc Company Information
7.5.2 Intravacc Introduction and Business Overview
7.5.3 Intravacc Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Intravacc Cell-based Flu Vaccine Product Offerings
7.5.5 Intravacc Recent Development
7.6 CSL Limited
7.6.1 CSL Limited Company Information
7.6.2 CSL Limited Introduction and Business Overview
7.6.3 CSL Limited Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 CSL Limited Cell-based Flu Vaccine Product Offerings
7.6.5 CSL Limited Recent Development
7.7 E. Merck KG
7.7.1 E. Merck KG Company Information
7.7.2 E. Merck KG Introduction and Business Overview
7.7.3 E. Merck KG Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 E. Merck KG Cell-based Flu Vaccine Product Offerings
7.7.5 E. Merck KG Recent Development
7.8 Novartis
7.8.1 Novartis Company Information
7.8.2 Novartis Introduction and Business Overview
7.8.3 Novartis Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Novartis Cell-based Flu Vaccine Product Offerings
7.8.5 Novartis Recent Development
7.9 Danaher Corporation
7.9.1 Danaher Corporation Company Information
7.9.2 Danaher Corporation Introduction and Business Overview
7.9.3 Danaher Corporation Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Danaher Corporation Cell-based Flu Vaccine Product Offerings
7.9.5 Danaher Corporation Recent Development
7.10 SINOVAC
7.10.1 SINOVAC Company Information
7.10.2 SINOVAC Introduction and Business Overview
7.10.3 SINOVAC Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 SINOVAC Cell-based Flu Vaccine Product Offerings
7.10.5 SINOVAC Recent Development
8 Industry Chain Analysis
8.1 Cell-based Flu Vaccine Industrial Chain
8.2 Cell-based Flu Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cell-based Flu Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Cell-based Flu Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Cell-based Flu Vaccine Market Trends
    Table 2. Cell-based Flu Vaccine Market Drivers & Opportunity
    Table 3. Cell-based Flu Vaccine Market Challenges
    Table 4. Cell-based Flu Vaccine Market Restraints
    Table 5. Global Cell-based Flu Vaccine Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Cell-based Flu Vaccine Revenue Market Share by Company (2019-2024)
    Table 7. Global Cell-based Flu Vaccine Sales Volume by Company (2019-2024) & (M Doses)
    Table 8. Global Cell-based Flu Vaccine Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Cell-based Flu Vaccine Price by Company (2019-2024) & (US$/Dose)
    Table 10. Key Manufacturers Cell-based Flu Vaccine Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Cell-based Flu Vaccine Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Cell-based Flu Vaccine
    Table 13. Global Cell-based Flu Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-based Flu Vaccine as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Cell-based Flu Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Cell-based Flu Vaccine Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Cell-based Flu Vaccine Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Cell-based Flu Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Cell-based Flu Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Cell-based Flu Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (M Doses)
    Table 22. Global Cell-based Flu Vaccine Sales Volume by Type (2019-2024) & (M Doses)
    Table 23. Global Cell-based Flu Vaccine Sales Volume by Type (2025-2030) & (M Doses)
    Table 24. Global Cell-based Flu Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Cell-based Flu Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Cell-based Flu Vaccine Price by Type (2019-2024) & (US$/Dose)
    Table 27. Global Cell-based Flu Vaccine Price by Type (2025-2030) & (US$/Dose)
    Table 28. Global Cell-based Flu Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Cell-based Flu Vaccine Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Cell-based Flu Vaccine Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Cell-based Flu Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Cell-based Flu Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Cell-based Flu Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (M Doses)
    Table 34. Global Cell-based Flu Vaccine Sales Volume by Application (2019-2024) & (M Doses)
    Table 35. Global Cell-based Flu Vaccine Sales Volume by Application (2025-2030) & (M Doses)
    Table 36. Global Cell-based Flu Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Cell-based Flu Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Cell-based Flu Vaccine Price by Application (2019-2024) & (US$/Dose)
    Table 39. Global Cell-based Flu Vaccine Price by Application (2025-2030) & (US$/Dose)
    Table 40. Global Cell-based Flu Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Cell-based Flu Vaccine Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Cell-based Flu Vaccine Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Cell-based Flu Vaccine Sales Value by Region (2019-2024) & (%)
    Table 44. Global Cell-based Flu Vaccine Sales Value by Region (2025-2030) & (%)
    Table 45. Global Cell-based Flu Vaccine Sales Volume by Region (M Doses): 2019 VS 2023 VS 2030
    Table 46. Global Cell-based Flu Vaccine Sales Volume by Region (2019-2024) & (M Doses)
    Table 47. Global Cell-based Flu Vaccine Sales Volume by Region (2025-2030) & (M Doses)
    Table 48. Global Cell-based Flu Vaccine Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Cell-based Flu Vaccine Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Cell-based Flu Vaccine Average Price by Region (2019-2024) & (US$/Dose)
    Table 51. Global Cell-based Flu Vaccine Average Price by Region (2025-2030) & (US$/Dose)
    Table 52. Key Countries/Regions Cell-based Flu Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Cell-based Flu Vaccine Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Cell-based Flu Vaccine Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Cell-based Flu Vaccine Sales Volume, (2019-2024) & (M Doses)
    Table 56. Key Countries/Regions Cell-based Flu Vaccine Sales Volume, (2025-2030) & (M Doses)
    Table 57. GlaxoSmithKline Company Information
    Table 58. GlaxoSmithKline Introduction and Business Overview
    Table 59. GlaxoSmithKline Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 60. GlaxoSmithKline Cell-based Flu Vaccine Product Offerings
    Table 61. GlaxoSmithKline Recent Development
    Table 62. Sanofi Company Information
    Table 63. Sanofi Introduction and Business Overview
    Table 64. Sanofi Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 65. Sanofi Cell-based Flu Vaccine Product Offerings
    Table 66. Sanofi Recent Development
    Table 67. Pfizer Company Information
    Table 68. Pfizer Introduction and Business Overview
    Table 69. Pfizer Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 70. Pfizer Cell-based Flu Vaccine Product Offerings
    Table 71. Pfizer Recent Development
    Table 72. MedImmune, LLC Company Information
    Table 73. MedImmune, LLC Introduction and Business Overview
    Table 74. MedImmune, LLC Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 75. MedImmune, LLC Cell-based Flu Vaccine Product Offerings
    Table 76. MedImmune, LLC Recent Development
    Table 77. Intravacc Company Information
    Table 78. Intravacc Introduction and Business Overview
    Table 79. Intravacc Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 80. Intravacc Cell-based Flu Vaccine Product Offerings
    Table 81. Intravacc Recent Development
    Table 82. CSL Limited Company Information
    Table 83. CSL Limited Introduction and Business Overview
    Table 84. CSL Limited Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 85. CSL Limited Cell-based Flu Vaccine Product Offerings
    Table 86. CSL Limited Recent Development
    Table 87. E. Merck KG Company Information
    Table 88. E. Merck KG Introduction and Business Overview
    Table 89. E. Merck KG Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 90. E. Merck KG Cell-based Flu Vaccine Product Offerings
    Table 91. E. Merck KG Recent Development
    Table 92. Novartis Company Information
    Table 93. Novartis Introduction and Business Overview
    Table 94. Novartis Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 95. Novartis Cell-based Flu Vaccine Product Offerings
    Table 96. Novartis Recent Development
    Table 97. Danaher Corporation Company Information
    Table 98. Danaher Corporation Introduction and Business Overview
    Table 99. Danaher Corporation Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 100. Danaher Corporation Cell-based Flu Vaccine Product Offerings
    Table 101. Danaher Corporation Recent Development
    Table 102. SINOVAC Company Information
    Table 103. SINOVAC Introduction and Business Overview
    Table 104. SINOVAC Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
    Table 105. SINOVAC Cell-based Flu Vaccine Product Offerings
    Table 106. SINOVAC Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Cell-based Flu Vaccine Downstream Customers
    Table 110. Cell-based Flu Vaccine Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Cell-based Flu Vaccine Product Picture
    Figure 2. Global Cell-based Flu Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Cell-based Flu Vaccine Sales Volume (2019-2030) & (M Doses)
    Figure 5. Global Cell-based Flu Vaccine Sales Price (2019-2030) & (US$/Dose)
    Figure 6. Cell-based Flu Vaccine Report Years Considered
    Figure 7. Global Cell-based Flu Vaccine Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Cell-based Flu Vaccine Players Sales Volume Ranking (2023) & (M Doses)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Cell-based Flu Vaccine Revenue in 2023
    Figure 10. Cell-based Flu Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Trivalent Influenza Vaccine Picture
    Figure 12. Quadrivalent Influenza Vaccine Picture
    Figure 13. Global Cell-based Flu Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Cell-based Flu Vaccine Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Cell-based Flu Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (M Doses)
    Figure 16. Global Cell-based Flu Vaccine Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Cell-based Flu Vaccine Price by Type (2019-2030) & (US$/Dose)
    Figure 18. Product Picture of Aldults
    Figure 19. Product Picture of Children
    Figure 20. Global Cell-based Flu Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 21. Global Cell-based Flu Vaccine Sales Value Market Share by Application, 2023 & 2030
    Figure 22. Global Cell-based Flu Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (M Doses)
    Figure 23. Global Cell-based Flu Vaccine Sales Volume Market Share by Application, 2023 & 2030
    Figure 24. Global Cell-based Flu Vaccine Price by Application (2019-2030) & (US$/Dose)
    Figure 25. North America Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 26. North America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 27. Europe Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 28. Europe Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 29. Asia Pacific Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 30. Asia Pacific Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 31. South America Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 32. South America Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 33. Middle East & Africa Cell-based Flu Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 34. Middle East & Africa Cell-based Flu Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 35. Key Countries/Regions Cell-based Flu Vaccine Sales Value (%), (2019-2030)
    Figure 36. Key Countries/Regions Cell-based Flu Vaccine Sales Volume (%), (2019-2030)
    Figure 37. United States Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 38. United States Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 39. United States Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 40. Europe Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Europe Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 42. Europe Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 43. China Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 44. China Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 45. China Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 46. Japan Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Japan Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 48. Japan Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 49. South Korea Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 50. South Korea Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 51. South Korea Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 52. Southeast Asia Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 53. Southeast Asia Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 54. Southeast Asia Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 55. India Cell-based Flu Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 56. India Cell-based Flu Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 57. India Cell-based Flu Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 58. Cell-based Flu Vaccine Industrial Chain
    Figure 59. Cell-based Flu Vaccine Manufacturing Cost Structure
    Figure 60. Channels of Distribution (Direct Sales, and Distribution)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SecuX Technology Inc